Does TECLISTAMAB-CQYV Cause Immune effector cell-associated neurotoxicity syndrome? 153 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 153 reports of Immune effector cell-associated neurotoxicity syndrome have been filed in association with TECLISTAMAB-CQYV. This represents 9.6% of all adverse event reports for TECLISTAMAB-CQYV.
153
Reports of Immune effector cell-associated neurotoxicity syndrome with TECLISTAMAB-CQYV
9.6%
of all TECLISTAMAB-CQYV reports
43
Deaths
67
Hospitalizations
How Dangerous Is Immune effector cell-associated neurotoxicity syndrome From TECLISTAMAB-CQYV?
Of the 153 reports, 43 (28.1%) resulted in death, 67 (43.8%) required hospitalization, and 12 (7.8%) were considered life-threatening.
Is Immune effector cell-associated neurotoxicity syndrome Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 153 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB-CQYV Cause?
Cytokine release syndrome (406)
Off label use (122)
Death (116)
Plasma cell myeloma (96)
Infection (83)
Neutropenia (74)
Fatigue (72)
Pyrexia (67)
Covid-19 (64)
Pneumonia (58)
What Other Drugs Cause Immune effector cell-associated neurotoxicity syndrome?
AXICABTAGENE CILOLEUCEL (1,821)
BREXUCABTAGENE AUTOLEUCEL (529)
CYCLOPHOSPHAMIDE (468)
TISAGENLECLEUCEL (416)
FLUDARABINE (331)
RITUXIMAB (305)
DEXAMETHASONE (267)
CILTACABTAGENE AUTOLEUCEL (232)
DOXORUBICIN (189)
PREDNISONE (179)
Which TECLISTAMAB-CQYV Alternatives Have Lower Immune effector cell-associated neurotoxicity syndrome Risk?
TECLISTAMAB-CQYV vs TEDIZOLID
TECLISTAMAB-CQYV vs TEDUGLUTIDE
TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER
TECLISTAMAB-CQYV vs TEGAFUR
TECLISTAMAB-CQYV vs TEGAFUR\URACIL